HC Pharma
ActiveFrom the official registers: KBO 47 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
The computed 12-month bankruptcy probability of HC Pharma is 3.2% (moderate). The 2025 annual accounts show negative equity (-€992,548) and a net result of -€235,534. Equity is growing by about 4.7% per year across the filed financial years. Its solvency ranks better than 9% of 12,737 sector peers (NACE 47, financial year 2025). The company has been active since 1961 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
24-07
Gazette deed
Resignation: BV ALEXO (director)Appointment: BV KST Pharma (director) · Reappointment: BV SODIAP (managing director) · Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis8 facts ▸
Gazette deed
Resignation: BV ALEXO (director)
Appointment: BV KST Pharma (director) · Reappointment: BV SODIAP (managing director) · Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis8 facts ▸
- General meeting, 19-05-2026
- Board meeting, 19-05-2026
- Director resignation, BV ALEXO (director)
- Director appointment, BV KST Pharma (director)
- Director reappointment, BV SODIAP (managing director)
- Permanent representative, Olivier Delaere
- Permanent representative, Koen Straetmans
- Permanent representative, Tom Goderis
12-05
financial year 2025 · abbreviated format
2025
16-06
financial year 2024 · abbreviated format
2024
11-06
financial year 2023 · abbreviated format
2023
09-06
financial year 2022 · abbreviated format
2022
02-12
Gazette deed
Appointment: Alexo BV (director)Permanent representatives: Olivier Delaere and Frank Coene · Resignation: Aristo BV (director)7 facts ▸
Gazette deed
Appointment: Alexo BV (director)
Permanent representatives: Olivier Delaere and Frank Coene · Resignation: Aristo BV (director)7 facts ▸
- General meeting, 30-08-2022
- Director appointment, Alexo BV (director)
- Permanent representative, Olivier Delaere
- Director resignation, Aristo BV (director)
- Permanent representative, Frank Coene
- Board meeting, 01-09-2022
- Director appointment, Alexo BV (chair of the board)
27-09
Gazette deed
Appointment: Louwagie Gilles (director)Permanent representatives: Gilles Louwagie and Tom Goderis7 facts ▸
Gazette deed
Appointment: Louwagie Gilles (director)
Permanent representatives: Gilles Louwagie and Tom Goderis7 facts ▸
- General meeting, 01-07-2022
- Director appointment, Louwagie Gilles (director)
- Permanent representative, Gilles Louwagie
- Board meeting, “daaropvolgende, raad van bestuur” (deed in Dutch)
- Director appointment, Louwagie Gilles (managing director)
- Permanent representative, Tom Goderis
- Director in office, Sodiap (managing director)
07-06
financial year 2021 · abbreviated format
2021
31-12
Financial
Highest result from 2018 to 2025net €156,837 ▲160%
Operating result €155,096, net result €156,837, both a record.
14-06
financial year 2020 · abbreviated format
2020
31-12
Financial
Back to profitnet €60,333
Net result €60,333 after 2 loss-making years.
13-07
financial year 2019 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank